Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

ASBP

Aspire Biopharma Holdings Inc

Jan 16 • 04:00PM ET

2.21

+0.13 6.45 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-25.66	Insider Own	81.30%	Shs Outstand	3.46M	Perf Week	-46.88%
Market Cap	7.65M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.09M	Perf Month	-47.03%
Enterprise Value	14.35M	PEG	-	EPS next Q	-	Inst Own	18.70%	Short Float	9.03%	Perf Quarter	-82.70%
Income	-20.50M	P/S	3940.83	EPS this Y	-	Inst Trans	-	Short Ratio	0.27	Perf Half Y	-84.57%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.28M	Perf YTD	-58.11%
Book/sh	-9.26	P/C	4.03	EPS next 5Y	-	ROE	334.80%	52W High	632.00 -99.65%	Perf Year	-99.52%
Cash/sh	0.55	P/FCF	-	EPS past 3/5Y	- -	ROIC	443.40%	52W Low	1.85 19.59%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	45.50%	Volatility	23.14% 18.50%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7392.66	EPS Y/Y TTM	-282.02%	Oper. Margin	-	ATR (14)	0.85	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.10	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.00	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.20	EPS Q/Q	-377.60%	SMA20	-45.09%	Beta	0.81	Target Price	-
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	-50.69%	Rel Volume	1.14	Prev Close	2.08
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	-83.01%	Avg Volume	1.04M	Price	2.21
IPO	Apr 11, 2022	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	1,180,819	Change	6.45%

Jan-14-26 08:00AM	Aspire Biopharma Announces Reverse Stock Split (ACCESSWIRE) -26.44%
Jan-07-26 08:00AM	Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) (ACCESSWIRE) +19.62%
Dec-18-25 08:30AM	Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine (ACCESSWIRE)
Dec-12-25 05:00PM	Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (ACCESSWIRE) -9.09% +13.05%
Dec-04-25 09:00AM	Aspire Biopharma Provides Q3 2025 Business Update (ACCESSWIRE)
09:00AM	Loading…
Dec-02-25 09:00AM	Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) (ACCESSWIRE)
Nov-26-25 09:00AM	Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member (ACCESSWIRE)
Nov-06-25 09:00AM	Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin (ACCESSWIRE) -23.87%
Oct-06-25 08:30AM	Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform (ACCESSWIRE)
Oct-03-25 11:30AM	Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025 (ACCESSWIRE) -8.62%
Oct-01-25 08:30AM	Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication (ACCESSWIRE)
Sep-17-25 08:30AM	Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product (ACCESSWIRE)
Sep-16-25 08:30AM	Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement (ACCESSWIRE) +8.11%
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-19-25 08:00AM	Sidoti Events, LLC's Virtual August Micro-Cap Conference (ACCESSWIRE) -20.90%
10:30AM	Loading…
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +64.35%
Aug-14-25 08:00AM	Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 (ACCESSWIRE)
Aug-13-25 09:10AM	Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World (ACCESSWIRE) +10.83%
Jul-31-25 08:30AM	Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement (ACCESSWIRE) -10.96%
Jul-30-25 07:45PM	Aspire Biopharma Holdings, Inc. Announces CEO Transition (ACCESSWIRE) -10.16%
Jul-25-25 12:22PM	Aspire Biopharma's BUZZ BOMB Shows Promising Initial Feedback (Insider Monkey)
Jul-22-25 10:45AM	Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World (ACCESSWIRE)
Jul-09-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement (ACCESSWIRE)
Jun-24-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE)
Jun-10-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer (ACCESSWIRE)
May-29-25 08:45AM	Aspire Biopharma provides development update on BUZZ BOMB supplement (TipRanks) -14.72%
May-28-25 08:30AM	Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025 (ACCESSWIRE) +197.43%
May-20-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE)
08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-08-25 08:00AM	Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21 (ACCESSWIRE)
08:30AM	Loading…
Apr-29-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire) -11.21%
Apr-14-25 08:30AM	Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17 (ACCESSWIRE) +5.07%
Apr-11-25 08:30AM	Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement (ACCESSWIRE) +11.32%
Apr-09-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE) +16.17%
Mar-20-25 08:30AM	Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice ('GMP') Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin (ACCESSWIRE)
Mar-13-25 08:30AM	Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform (ACCESSWIRE) -21.62%
Mar-11-25 08:00AM	An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation (Newsfile)
Mar-03-25 07:30AM	Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement (ACCESSWIRE) -32.67%
Feb-25-25 07:30AM	Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin (ACCESS Newswire) -21.43%
Feb-20-25 06:15PM	Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement (ACCESSWIRE) -33.33% -58.44%
07:30AM	Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq (ACCESSWIRE)
Feb-19-25 01:10PM	Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq (ACCESSWIRE)
Sep-03-24 08:01AM	Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements (GlobeNewswire)
Jul-31-24 08:01AM	Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp. (GlobeNewswire)
Jun-05-24 04:05PM	PowerUp Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-20-24 05:11PM	PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders (GlobeNewswire)
May-16-24 04:05PM	PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders (GlobeNewswire) +7.62%
Jan-29-24 08:01AM	PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination (GlobeNewswire)
Dec-27-23 08:01AM	Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp. (GlobeNewswire)

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASBP

Aspire Biopharma Holdings Inc

Upgrade your FINVIZ experience